Archive for the ‘Treatment’ Category

Antiviral Effects of Nattokinase

https://petermcculloughmd.substack.com/p/antiviral-effects-of-nattokinase

Antiviral Effects of Nattokinase

Inhibition of SARS-CoV-2 and Bovine Herpes Virus-1 Demonstrated in Vitro

MAY 3, 2023

By Peter A. McCullough, MD, MPH

Recently there has been intense focus on “natto” derived from the fermentation of steamed soy by bacillus subtilis. Nattokinase is a proteolytic enzyme used as an oral supplement by the Japanese for the chronic treatment of atherothrombotic cardiovascular disease. Now a recent study in the COVID-19 era by the Japanese demonstrated preventive antiviral effects against SARS-CoV-2 mutant strains and bovine herpes virus type 1. The mechanism appears to be proteolytic cleavage of viral proteins.

Oba and colleagues performed a series of experiments with various concentrations of nattokinase in preclinical models. They found: 1) nattokinase effectively stopped infection of human cells in culture from SARS-CoV-2 and bovine herpes virus type 1, 2) the proteolytic effect of nattokinase was heat sensitive.  (See link for article)

_________________

**Comment**

Besides having an ability to help “vaccine” injuries and prevent COVID and other viruses, Nattokinase and other proteolytic enzymes have been used by Lyme literate doctors (LLMD) for their role in breaking downbiofilm, the protective colonies many bacteria create which make them hard to eradicate.  Some use the zero-calorie sugar stevia for this purpose as well.

McCullough states that while it’s too early to make therapeutic claims, he says Nattokinase is the most promising data seen among all solutions to end the final state of the crisis: long COVID, “vaccine” injury, and recurrent infections.  For this reason don’t expect it to become mainstream!  This is precisely why they gave ivermectin and HCQ the death toll.  These, cheap, safe, effective drugs just do too many things that compete with the spin of Big Pharma, bought out government health agencies, and Big Media.

Study here:  https://pubmed.ncbi.nlm.nih.gov/34271432/

Case Report: Lyme Disease Causes Inflammation of the Spinal Cord

https://danielcameronmd.com/lyme-disease-inflammation-spinal-cord/

CASE REPORT: LYME DISEASE CAUSES INFLAMMATION OF THE SPINAL CORD

lyme-disease-spinal-cord
There have only been 8 documented pediatric cases of Lyme disease causing transverse myelitis. In this report, the authors describe the ninth case involving a 10-year-old boy.

In their article “Case report: Subacute transverse myelitis with gait preservation secondary to Lyme disease and a review of the literature,” Colot and colleagues describe a 10-year-old boy who suffered from neck pain with irradiation in the upper limbs for 13 days.

Transverse myelitis (TM) is an inflammation of both sides of one section of the spinal cord. Diagnosis requires clinical symptoms and evidence of inflammation within the spinal cord via cerebrospinal fluid analysis and/or magnetic resonance imaging.

Treatment of transverse myelitis typically includes oral steroids, intravenous immunoglobulins, plasma exchange, and immunomodulatory therapies.

“Clinical features consist of sensory disturbances in most patients, followed by weakness and sphincter dysfunction. Children suffer from more severe clinical impairment than adults,” the authors wrote.

In fact, one study found 89% of the pediatric patients were bed- or wheelchair-bound or required assisted ventilation.

In this case report, Colot et al. provides evidence that the clinical presentation of neuroborrelial transverse myelitis differs from classical TM.

“TM secondary to Lyme disease is more often subacute with gait preservation and is limited to the cervical spine,” the authors wrote.

Lyme disease triggers inflammation in spinal cord

A 10-year-old boy presented to his pediatrician with “persistent nocturnal and rotational neck pain with irradiation in the upper limbs for 13 days with a feeling of heaviness and paresthesia in the fingers.”

The boy also had a fever for 11 days, along with fatigue and headaches.

MRI findings of the spine suggested longitudinal extensive transverse myelitis (LETM).

“A spinal MRI showed an extensive T2 hypersignal between C1 and C7, with a normal T1 signal confirming the diagnosis of LETM.”

An extensive workup was performed using blood serologies and autoimmune factors. A CSF analysis found an increased white blood cell count in cerebrospinal fluid.

“The patient was treated with high-dose methylprednisolone IV for 5 days and Ceftriaxone IV,” the authors wrote. After 48 hours, the boy’s symptoms decreased, his CSF bacterial culture was negative and Ceftriaxone was stopped.

He remained on steroids but 2 days later, his neck pain and laterocollis (head tilted to one side) reappeared.

“Our case illustrates that neuroborrelial TM should be treated with long-term [antibiotic] therapy and that steroids do not seem to improve the prognosis.”

Since the patient lived in a tick-endemic area, he was tested for Lyme disease.

“The test results of Borrelia IgG in the blood and intrathecal IgG synthesis were positive, confirming the diagnosis of TM secondary to Lyme disease,” the authors explained.

“The patient reported that he had an erythematous spot in the neck a few months back, which was suggestive of an erythema migrans, but he did not remember that he had suffered from a tick bite,” the authors explained.

After 23 days of treatment with Ceftriaxone and Doxycycline, the patient made a complete recovery.

Authors Conclude:

“After an extensive review of the pediatric literature, we wish to emphasize five aspects of TM secondary to Lyme disease:”

  1. presentation is more often subacute
  2. lesions are mainly located in the cervical spine
  3. gait is usually preserved
  4. sphincter dysfunction is unusual
  5. recovery is usually complete after prolonged antibiotic therapy

The authors suggest: “[Transverse myelitis] in a subacute presentation, gait preservation, a discrepancy between the severe mainly cervical imaging manifestations and the minimal clinical signs and symptoms, and the absence of sphincter dysfunction should raise suspicion of TM secondary to Lyme disease.”

References:
  1. Colot C, Adler C, Mignon C, De Leucio A, Jissendi P, Fonteyne J, Aeby A. Case report: Subacute transverse myelitis with gait preservation secondary to Lyme disease and a review of the literature. Front Pediatr. 2023 Mar 16;11:1064234. doi: 10.3389/fped.2023.1064234. PMID: 37009275; PMCID: PMC10061057.

_______________

**Comment**

This patient, like all others presented in the literature, needs extensive follow-up, which never happens in mainstream medicine and/or research.  My hunch is this poor kid will have symptoms later on that will never be connected to this event.  I pray I’m wrong.

Further, nothing is mentioned about coinfections, which are the norm not the exception.

Whistleblower Nurse on Health Care Corruption

http://  Approx. 25 Min

Nurse on Health Care Corruption

April 18, 2023

Gail Macrae is a California nurse turned whistleblower who was fired for refusing to take the COVID-19 shot. She joined Liz Collin this week to discuss what she witnessed while working in health care during the pandemic.

  • She refutes the media’s claim that hospitals were overflowing during COVID
  • Her hospital in particular was under utilized
  • It’s completely normal to have empty hospitals in the Spring and Summer and then to have patients in the winter months
  • She witnessed first hand the horrific results of isolating patients by not allowing family members at their bedsides.
  • Remdesivir didn’t not help patients improve but actually caused multi-organ failure.  She was told it was “protocol.”  This protocol still exists today despite its danger and ineffectiveness.
  • She mentions finding out about the financial kickbacks hospitals received.
  • Her hospital had 3 TIMES the admission rate within 2 weeks after the COVID injections were rolled out than at any time in history.
  • Anaphylaxis was common.  A nurse was told if she reported these she would be fired.
  • Staff were afraid of losing their livelihood and mostly went along with the tyranny.  Many left the field.
  • Standfirmnow.org is Macrae’s latest endeavor.
“May our children never say we were cowards in the face of evil.” ~ Lieutenant Colonel Theresa Long, MD
  • She mentions the FLCCC website for helpful resources including COVID treatments and the importance of addressing the significant inflammation caused by COVID.

For more:

Study: SOT Potential Treatment For Viruses & Lyme Disease

https://pubmed.ncbi.nlm.nih.gov/36412742/

Supportive Oligonucleotide Therapy (SOT) as a Potential Treatment for Viral Infections and Lyme Disease: Preliminary Results

Free PMC article

Abstract

Antisense therapy is widely used as an alternative therapeutic option for various diseases. RNA interference might be effective in infections, through the degradation of messenger RNA and, therefore, translation process. Hence, proteins essential for microorganisms and viruses’ proliferation and metabolism are inhibited, leading to their elimination. The present study aimed to evaluate the use of oligonucleotide in patients infected by Epstein-Barr (EBV) or Herpes Simplex Viruses 1/2 or with Lyme Disease caused by Borrelia burgdorferi. Blood samples were collected from 115 patients and the different species were characterized using molecular biology techniques. Then, SOT molecules (Supportive Oligonucleotide Therapy), which are specific small interfering RNA (siRNA), were designed, produced, and evaluated, for each specific strain. Oligonucleotides were administered intravenously to patients and then a quantitative Polymerase Chain Reaction was used to evaluate the effectiveness of SOT. This study revealed that for Lyme Disease, one or two SOT administrations can lead to a statistically significant decrease in DNA copies, while for viruses, two or three administrations are required to achieve a statistically significant reduction in the genetic material. These preliminary results indicate that antisense SOT therapy can be considered a potential treatment for viral as well as Lyme diseases.

For more:

The challenge with Lyme is correctly identifying the patient’s infections as they are typically coinfected with many. Further, it’s all based on using PCR to detect the DNA of various bacteria which is known to find Lyme only 30% of the time.  Further, many of the organisms with Lyme/MSIDS aren’t found in the blood so trying to detect it there is futile (another reason this is so hard to test, diagnose, and treat.)

Using genetic code for a treatment for this is like trying to catch a greased pig.  Lyme in particular changes its outer surface protein which means what goes into you isn’t what comes out of you as the organism mutates to survive.  Yet another reason it’s difficult treating this and why there has never and will never be a Lyme vaccine worth its weight in salt.  You can’t pin something down that changes.

Personally, all this work on treatments using genetics scares the bajeebers out of me.  Hopefully the past three years have caused all of us to pause and consider the implications of using genes and their ability to alter genetic code.  Also, what works in a petri dish often doesn’t work in reality.

Of course, at the end of the day, we are all big boys and girls and have to make our own decisions.  What works for one often doesn’t work for another and if you do your reading, are convinced of its merits, and want to try this, then by all means do it.  If you have success, or if you don’t, please let me know.  Often the best way we move forward is by educating one another on various treatments and health changes.

Shape-Shifting Antibiotics?

https://www.pnas.org/doi/10.1073/pnas.2208737120

Shapeshifting bullvalene-linked vancomycin dimers as effective antibiotics against multidrug-resistant gram-positive bacteria

Edited by Kyriacos Nicolaou, Rice University, Houston, TX; received May 20, 2022; accepted February 24, 2023
April 3, 2023
120 (15) e2208737120
Abstract
The alarming rise in superbugs that are resistant to drugs of last resort, including vancomycin-resistant enterococci and staphylococci, has become a significant global health hazard. Here, we report the click chemistry synthesis of an unprecedented class of shapeshifting vancomycin dimers (SVDs) that display potent activity against bacteria that are resistant to the parent drug, including the ESKAPE pathogens, vancomycin-resistant Enterococcus (VRE), methicillin-resistant Staphylococcus aureus (MRSA), as well as vancomycin-resistant S. aureus (VRSA). The shapeshifting modality of the dimers is powered by a triazole-linked bullvalene core, exploiting the dynamic covalent rearrangements of the fluxional carbon cage and creating ligands with the capacity to inhibit bacterial cell wall biosynthesis. The new shapeshifting antibiotics are not disadvantaged by the common mechanism of vancomycin resistance resulting from the alteration of the C-terminal dipeptide with the corresponding d-Ala-d-Lac depsipeptide. Further, evidence suggests that the shapeshifting ligands destabilize the complex formed between the flippase MurJ and lipid II, implying the potential for a new mode of action for polyvalent glycopeptides. The SVDs show little propensity for acquired resistance by enterococci, suggesting that this new class of shapeshifting antibiotic will display durable antimicrobial activity not prone to rapidly acquired clinical resistance.